ADA Members Launch Formal Boycott Over Unresolved Conference Ejection Dispute

Key points

• The boycott, effective immediately, includes over 400 signatories, including past presidents, award winners, and the four editors of Diabetes Care, who have suspended manuscript reviews.
• The dispute originated in June when police removed five researchers, including Diabetes Care editor-in-chief Steven Kahn, for distributing an editorial criticizing federal research funding cuts.
• Signatories pledge to suspend all ADA-related activities, including the 2027 Scientific Sessions, until the board permits an independent formal review of the organization’s structure and function.
• The ADA’s internal investigation initially concluded the removals were due to code-of-conduct violations, but later acknowledged the findings did not reflect the full breadth of the inquiry, leading to a swift retraction of that stance.
• If the ADA does not meet demands for structural reform, signatories plan to align with other medical societies, such as the Endocrine Society or American Heart Association.

Background

This escalation follows months of tension after the June 2026 ADA Scientific Sessions in New Orleans. Earlier coverage noted that over 8,000 supporters had signed a Change.org petition and more than 500 members demanded the resignation of CEO Charles Henderson and an independent investigation. The current boycott represents a shift from petitions to active operational disruption, including the suspension of journal reviews and grant evaluations.

How outlets are covering it

MedPage Today and STAT emphasize the operational impact of the boycott, highlighting the suspension of manuscript reviews and the removal of notices by the ADA. Fierce Biotech focuses on the political dimension, noting Kahn’s comparison of the situation to apartheid-era suppression of free speech and the potential for members to splinter into other organizations. DocWireNews offers a more measured perspective, with Dr. Melanie Jay arguing that while the response was disproportionate, the ADA has taken initial steps to review the incident and should focus on rebuilding trust rather than facing a total boycott. The ADA itself maintains a neutral stance, stating it is aware of the boycott but remains focused on serving the millions of people relying on its mission.

Why it matters

The boycott threatens the stability of a major medical society and could lead to a fragmentation of the diabetes research community. It raises critical questions about the balance between conference conduct policies and the protection of scientific discourse, particularly regarding policy-related topics. The outcome may set a precedent for how professional societies handle internal dissent and the role of independent governance in maintaining trust among members.

What to watch

The ADA is expected to release a final report on its internal investigation in the coming weeks. The boycott will remain active until the board permits an independent formal review of the organization’s structure and function. If demands are not met, signatories plan to align with existing or newly formed medical societies, potentially leading to a significant shift in the diabetes research community.